Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children ≥ 6 months old and \< 12 years old~* Past history of proven congenital CMV infection~* Auditory threshold of between 40 and 90 dB in at least 1 ear.~Exclusion Criteria:~* Bilateral deafness \> 90 dB~* Contraindication to valganciclovir, particularly: Neutropenia with a known neutrophil count of \<500/mm3, Hb\<8g/dl or platelets\< 25,000/mm3 (FBC to be confirmed before randomisation)~* Past history of neutropenia on valganciclovir or allergy to the compound~* Renal impairment with creatinine clearance of \< 10 ml/min/1.72m2 (confirmation of renal function before randomisation) according to the Schwartz equation~* Patients on other antiviral treatment~* Gastrointestinal absorption problems~* Patients participating in a biomedical research project on a medicinal product or similar product

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Valganciclovir (Type: EXPERIMENTAL): Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension), at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
- Control group (Type: NO_INTERVENTION): Control group with standard care who do not receive the investigational medicinal product

Based on this trial design, predict the completion outcome and termination type (if applicable).